Patents Assigned to MedImmune, Inc.
-
Patent number: 7323172Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: October 8, 2004Date of Patent: January 29, 2008Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Publication number: 20080003210Abstract: The present invention relates to novel non-human primate receptor tyrosine kinases. In particular, the present invention relates to Rhesus EphA2 and Cynomolgus EphA2 nucleotide and amino acid sequences.Type: ApplicationFiled: March 12, 2007Publication date: January 3, 2008Applicant: MedImmune, Inc.Inventors: Elizabeeth Bruckheimer, William Walsh, Michael Kinch
-
Patent number: 7309490Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.Type: GrantFiled: August 8, 2005Date of Patent: December 18, 2007Assignee: MedImmune, Inc.Inventor: Scott Koenig
-
Patent number: 7297337Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.Type: GrantFiled: September 23, 2005Date of Patent: November 20, 2007Assignees: MedImmune, Inc., University of Pittsburgh-of the Commonwealth System of Higher EducationInventors: Walter J Storkus, Michael S Kinch
-
Patent number: 7294336Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.Type: GrantFiled: February 24, 2006Date of Patent: November 13, 2007Assignee: MedImmune, Inc.Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
-
Publication number: 20070202122Abstract: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.Type: ApplicationFiled: September 21, 2006Publication date: August 30, 2007Applicant: MEDIMMUNE, INC.Inventors: Richard Spaete, Winthrop Jackman
-
Publication number: 20070196916Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: December 20, 2006Publication date: August 23, 2007Applicant: MedImmune, Inc.Inventors: James Young, Scott Koenig, Leslie Johnson, William Huse, Jeffrey Watkins, Herren Wu
-
Patent number: 7229619Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: November 28, 2000Date of Patent: June 12, 2007Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Patent number: 7229618Abstract: The present invention provides crystalline forms and three-dimensional atomic structure coordinates of Synagis Fab. The present invention further provides methods of using such three-dimensional atomic structure coordinates for designing and identifying Synagis binding agents. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab and methods of using them.Type: GrantFiled: August 17, 2005Date of Patent: June 12, 2007Assignees: Medimmune, Inc., Bowie State UniversityInventors: Leslie S. Johnson, Bradford Braden
-
Publication number: 20070122403Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: ApplicationFiled: January 3, 2007Publication date: May 31, 2007Applicant: MedImmune, Inc.Inventors: William Dall'Acqua, Leslie Johnson, Elizabeth Ward
-
Publication number: 20070111260Abstract: The present invention relates to a viral vector encoding for a library of antibodies or antibody fragments that are displayed on the cell membrane when expressed in a cell. The present invention provides cells comprising the viral vector nucleic acids and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.Type: ApplicationFiled: October 13, 2006Publication date: May 17, 2007Applicant: MEDIMMUNE, INC.Inventors: Changshou Gao, Herren Wu
-
Publication number: 20070092523Abstract: Therapeutically effective anti-microbial compositions, useful especially against respiratory diseases caused or mediated by viruses, bacteria, and other respiratory parasites are disclosed, wherein said compositions comprise at least one neutralizing antibody, including high affinity antibodies, and an additional anti-infectious agent, such as an antiviral agent, for example, ribavirin, amantadine, rimantadine, or a neuraminidase-inhibitor. or antibacterial agents, including other antibodies. Also disclosed are methods of using such compositions to treat and/or prevent respiratory and related diseases.Type: ApplicationFiled: November 22, 2006Publication date: April 26, 2007Applicant: MEDIMMUNE, INC.Inventor: Leslie Johnson
-
Patent number: 7208162Abstract: Therapeutically effective anti-viral compositions, useful especially against respiratory diseases caused or mediated by respiratory syncytial virus (RSV) are disclosed, wherein said compositions comprise at least one anti-RSV antibody, including high affinity antibodies, and an additional anti-inflammatory agent, especially corticosteroids, as well as anti-inflammatory antibodies, especially anti-interleukin-6. Also disclosed are methods of using such compositions to treat and/or prevent respiratory diseases. Such compositions may optionally contain other non-antibody anti-viral agents.Type: GrantFiled: May 3, 2001Date of Patent: April 24, 2007Assignees: MedImmune, Inc., Virion Systems, Inc.Inventors: Gregory Prince, Leslie S. Johnson
-
Publication number: 20070071746Abstract: The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL-13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for the prevention, management, treatment or amelioration of an inflammatory condition associated with the upregulation of a C/CLP or one or more symptoms thereof and/or the inhibition of IL-13 mediated inflammation.Type: ApplicationFiled: August 30, 2006Publication date: March 29, 2007Applicant: MEDIMMUNE, INC.Inventors: Jennifer Reed, Wendy White, Anthony Coyle, Alexander Kozhich, Jack Elias
-
Patent number: 7179900Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: March 31, 2003Date of Patent: February 20, 2007Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins, Herren Wu
-
Publication number: 20070020279Abstract: This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb 1129 and the use thereof for the prevention and/or treatment of RSV infection.Type: ApplicationFiled: August 8, 2005Publication date: January 25, 2007Applicant: MEDIMMUNE, INC.Inventor: Leslie Johnson
-
Patent number: 7132100Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.Type: GrantFiled: June 13, 2003Date of Patent: November 7, 2006Assignee: MedImmune, Inc.Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
-
Patent number: 7132107Abstract: The present invention relates to novel immunogenic polypeptides, and fragments thereof, and vaccines for the prevention and treatment of pneumococcal infection, especially by Streptococcus pneumoniae. The invention also relates to antibodies against the disclosed polypeptides, as well as vaccines containing said polypeptides and methods of disease prevention.Type: GrantFiled: February 5, 2002Date of Patent: November 7, 2006Assignees: MedImmune, Inc., Human Genome Sciences, Inc.Inventors: John E. Adamou, Gil H. Choi
-
Publication number: 20060240446Abstract: Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for Preventing HCMV infections.Type: ApplicationFiled: December 5, 2005Publication date: October 26, 2006Applicant: MEDIMMUNE, INC.Inventors: Richard Spaete, Tai-An Cha
-
Patent number: 7122194Abstract: A vaccine composition is disclosed that comprises polypeptides and fragments of polypeptides containing histidine triad residues or coiled-coil regions, some of which polypeptides or fragments lie between 80 and 680 residues in length. Also disclosed are processes for preventing infection caused by S. pneumoniae comprising administering of vaccine compositions.Type: GrantFiled: April 14, 2003Date of Patent: October 17, 2006Assignee: MedImmune, Inc.Inventors: Leslie S. Johnson, John E. Adamou